For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Melanotan II (MT-II) is a synthetic cyclic lactam analog of alpha-melanocyte-stimulating hormone, developed in the late 1980s at the University of Arizona. It is the parent compound from which bremelanotide (PT-141, FDA-approved for HSDD) was derived. MT-II has Phase 1 and small Phase 2 human data demonstrating reliable skin tanning (Dorr et al., 1996) and potent erectogenic effects (Wessells et al., 1998 and 2000). Clinical development was formally abandoned due to the combination of severe nausea side effects and melanoma safety concerns. It is now sold exclusively through unregulated grey markets, a status associated with documented product contamination, dosing inaccuracy, eruptive naevi, and case reports of melanoma.
Melanotan II is the most clinically important compound in this database that has no approved use anywhere in the world and carries documented serious safety signals. The melanoma risk is contested but real enough that multiple national regulatory bodies -- FDA, TGA, MHRA -- have issued explicit public warnings. Clinical development was halted for safety reasons, not for lack of efficacy. The compound works. The safety concerns stopped it.
The melanoma signal comes from case reports, not controlled trials, which means causation cannot be established with certainty. What is established: MT-II stimulates melanocyte activity systemically; multiple published case reports document eruptive melanocytic naevi (new moles, rapidly, multiple), dysplastic naevi, and at least one melanoma case in a 20-year-old woman following a 3 to 4-week MT-II course combined with sunbed use (Hjuler and Lorentzen, 2014, Dermatology). The TGA statement is unambiguous: development was halted due to safety reasons. The FDA considers it an unapproved new drug and has pursued criminal prosecution of distributors.
The unregulated market compounds the risk substantially. Laboratory analysis of commercially available MT-II vials has documented that actual MT-II content ranges from 4.32 to 8.84 mg in vials claiming to contain 10 mg -- meaning users may receive 43% to 88% of the stated dose, or unknown impurities. Needle-sharing for injection compounds bloodborne disease transmission risk. These are not theoretical risks; they are documented in the peer-reviewed literature on MT-II use in gyms and tanning communities.
For completeness: the erectile dysfunction pharmacological finding from the Wessells trials (1998, 1999, 2000) is genuine and scientifically important. It led directly to bremelanotide (PT-141, Vyleesi), which completed the clinical development path that MT-II's safety profile blocked. The science worked; the drug's specific profile did not. That distinction matters for readers interested in the mechanism.
Melanotan II was synthesized in the late 1980s at the University of Arizona by Mac Hadley, Victor Hruby, and colleagues as part of a systematic program to develop superpotent alpha-MSH analogs. The University of Arizona's dermatology department, led by Norman Levine, was interested in developing a 'sunless tanning' agent that could protect fair-skinned people from UV-induced skin damage without requiring UV exposure. The cyclic lactam structure of MT-II (contrasted with the linear structure of afamelanotide / Melanotan I) conferred both greater potency and broader receptor selectivity.
The discovery of MT-II's erectogenic properties was accidental. During pilot tanning studies, the dermatologist Norman Levine observed that male subjects receiving MT-II developed unexpected, spontaneous erections. This serendipitous finding -- erections as a side effect of a tanning drug -- prompted the formal erectile dysfunction research program and ultimately led to the identification of melanocortin receptors (particularly MC4R) as central mediators of penile erection.
Clinical development passed through the University of Arizona program and was eventually licensed. The company Competitive Technologies held rights and worked with academic partners. However, clinical development was discontinued: the Australian TGA explicitly states development was halted for safety reasons. The sexually selective metabolite of MT-II, bremelanotide (PT-141), was separated from the development path and pursued independently by Palatin Technologies, eventually receiving FDA approval in 2019 as Vyleesi for HSDD in premenopausal women (profiled separately at order 21 in this database). MT-II itself has been abandoned by all commercial developers and is now exclusively a grey-market research chemical.
Melanotan II acts as a non-selective agonist at the melanocortin receptors. Unlike afamelanotide (Melanotan I), which has high selectivity for MC1R, MT-II binds with significant affinity to MC1R, MC3R, MC4R, and to a lesser degree MC5R. This non-selective profile is both the source of its broad biological effects and the mechanistic basis for its safety concerns.
MC1R activation in melanocytes is the tanning mechanism. MC1R is a G-protein-coupled receptor expressed on melanocytes in the skin and hair follicles. Agonist binding activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates CREB (cAMP response element-binding protein). This transcription factor upregulates tyrosinase and other melanogenic enzymes, shifting melanogenesis toward eumelanin (brown-black pigment) from pheomelanin (red-yellow pigment). The result is skin darkening that persists for weeks to months after MT-II discontinuation because melanin itself is stable. Crucially, MT-II can initiate melanin synthesis without UV exposure, though UV co-exposure substantially amplifies the response.
MC4R activation in the brain is responsible for the erectogenic and libido-enhancing effects. MC4R is expressed in hypothalamic, limbic, and brainstem nuclei involved in sexual behavior regulation. Activation of paraventricular nucleus MC4R receptors triggers oxytocin release and modulates dopaminergic pathways, ultimately activating pro-erectile autonomic pathways in the spinal cord. This central mechanism produces erections without peripheral genital stimulation -- a pharmacologically distinct route from phosphodiesterase-5 inhibitors (sildenafil, tadalafil), which act peripherally. MT-II produces the stretching-yawning complex that characteristically co-occurs with spontaneous erections, confirming the central origin of this effect.
MC3R activation in the hypothalamus and gut mediates appetite suppression and metabolic effects. MC3R signaling reduces food intake and affects energy balance. Nausea -- the most common side effect of MT-II -- is likely mediated through MC3R and MC4R receptors in the brainstem area postrema (vomiting center) and through direct hypothalamic activation.
The melanoma concern is mechanistic, not just observational. MC1R activation stimulates melanocyte proliferation and shifts the balance toward eumelanin. In individuals with pre-existing dysplastic nevi or genetic predisposition (certain MC1R polymorphisms, family history of melanoma), stimulating melanocyte activity with a compound hundreds of times more potent than endogenous alpha-MSH could theoretically accelerate malignant transformation. This is not proven causally in humans but is mechanistically plausible and supported by animal model data.
The Wessells 1998 study (n=10, psychogenic ED) is the first controlled human study of MT-II erectogenic properties. In 8 of 10 men treated with MT-II, clinically apparent erections developed as defined by RigiScan criteria. Mean duration of tip rigidity greater than 80% was 38.0 minutes with MT-II vs. 3.0 minutes with placebo (p=0.0045). These erections occurred without visual sexual stimulation, confirming that MT-II is a true central initiator of erection rather than an erectile facilitator like PDE5 inhibitors.
The Wessells 2000 study (n=20, mixed ED) extended these findings to organic erectile dysfunction. MT-II initiated spontaneously reported erections in 17 of 20 men. Subjects experienced a mean of 41 minutes of RigiScan tip rigidity greater than 80%. Increased sexual desire was reported after 13/19 (68%) MT-II doses vs. 4/21 (19%) of placebo doses (p less than 0.01). The study confirmed that the erectogenic mechanism is not limited to psychogenic ED: men with vascular, neurogenic, and hormonal organic risk factors responded.
The side effect finding at the clinically preferred dose: at 0.025 mg/kg, nausea occurred in the majority of subjects. In the pooled Wessells 2000 analysis, 12.9% of subjects had severe nausea. This nausea was the primary pharmacological limitation that prevented clinical development. The research team noted: 'side effects like nausea mean that this is not the best product to use' -- an accurate summation of why bremelanotide (PT-141), which was designed to minimize nausea while preserving sexual function, was developed as the clinical successor.
These findings are pharmacologically important because they demonstrated for the first time that centrally acting melanocortin agonism can produce penile erection in humans. This established MC4R as a validated erectile drug target and directly enabled bremelanotide's development.
The erectogenic pharmacology of MT-II is well-established in two placebo-controlled crossover trials (n=10 and n=20). Erections in 8/10 and 17/20 men without sexual stimulation, with RigiScan-confirmed rigidity, is a robust pharmacological finding. The limitation is not the science -- it is the side effect profile (severe nausea in approximately 13% of doses) combined with the melanoma safety concern that together ended development. Bremelanotide (PT-141) addressed the nausea problem through structural modification and received FDA approval for a related indication.
Eruptive melanocytic naevi following MT-II use is the most consistently documented clinical finding in the case report literature. Multiple cases describe the rapid development of dozens to more than 100 new melanocytic lesions over weeks of MT-II use -- a dermatological event that is highly unusual in adults without MT-II exposure. This finding is biologically plausible: MC1R activation stimulates melanocyte proliferation and shifts pigment synthesis toward eumelanin; a compound 1,000 times more potent than endogenous alpha-MSH would be expected to produce marked melanocyte stimulation.
The melanoma case (Hjuler and Lorentzen, 2014) involves a 20-year-old woman who combined MT-II with sunbed use and developed histologically confirmed melanoma. The concurrent UV exposure complicates causation attribution -- sunbed use alone is a known melanoma risk factor. However, the patient's age (20), the short interval (3 to 4 weeks of MT-II use), and the coincidence with intense melanocyte stimulation from both MC1R agonism and UV are noted by the authors as a concerning combination.
The regulatory consequence is unambiguous. The TGA's statement that MT-II development was halted for safety reasons aligns with the FDA's classification of MT-II as an unapproved new drug with documented safety concerns. The FDA's Adverse Event Reporting System includes tanning injections as 'potentially dangerous.' The MHRA (UK) and TGA have both issued public warnings.
Important epistemic note: case reports cannot establish causation. Multiple individuals with dysplastic naevi and melanoma history use tanning beds, which independently cause both eruptive naevi and melanoma. What can be said: the mechanistic concern is real and biologically grounded; multiple regulatory bodies have judged the concern sufficient to warrant warnings and development halt; the absolute risk in MT-II users is unknown because no controlled long-term study has been conducted.
The melanoma/naevi safety concern is the primary reason MT-II has no approved use. Causation has not been established in controlled trials. The mechanistic concern (superpotent melanocyte stimulation in a compound 1,000x more potent than endogenous alpha-MSH) is biologically grounded. Multiple published case reports document the naevi signal. Multiple regulatory bodies have acted on this concern. The magnitude of actual risk is unknown. For users: this is not a solved safety question in either direction.
The Dorr 1996 Phase 1 study established that MT-II produces measurable tanning in humans after only 5 low doses every other day. Two of three subjects showed increased pigmentation in the face, upper body, and buttocks by quantitative reflectance measurement and visual perception 1 week after MT-II dosing ended. The tanning effect was confirmed at subclinical doses (starting at 0.01 mg/kg) that produced modest pigmentation without significant UV exposure.
The critical pharmacological distinction from afamelanotide (Melanotan I): both compounds stimulate MC1R and produce tanning, but MT-II also activates MC3R and MC4R, producing the additional effects (appetite suppression, sexual arousal, nausea, erections) that afamelanotide's selective MC1R profile largely avoids. The tanning itself is real and has been documented across multiple clinical studies. However, the original photoprotection rationale for developing MT-II (protecting fair-skinned people from UV damage) is undermined by the melanoma safety concern: a drug that may facilitate melanoma is not a suitable skin cancer prevention agent.
The grey-market tanning use requires co-administration with UV exposure for full effect. MT-II primes melanocytes for rapid tanning, but in most protocols users still require some UV exposure (sunlight or tanning beds) to achieve the full tanning response. This co-administration pattern compounds melanoma risk: concurrent superpotent melanocyte stimulation with UV-induced DNA damage is the combination documented in the melanoma case report.
The tanning efficacy is genuine and documented in the Phase 1 study. The original intended application was photoprotection -- but the safety concerns, particularly the melanoma signal, make MT-II unsuitable as a photoprotective agent. The grey-market tanning use involves co-exposure to UV, which combines two independent melanoma risk factors. Afamelanotide (Scenesse, profile #20 in this database) represents the clinically approved and safer MC1R-selective alternative for photoprotection in EPP.
Sexual arousal in women: Hadley's 2005 PNAS paper documenting melanocortin effects on human sexual function included observations in women with sexual arousal disorder showing increased sexual desire and genital arousal following MT-II. This is the mechanistic foundation that led Palatin Technologies to study bremelanotide in women specifically. The female data for MT-II itself is limited -- bremelanotide received FDA approval for HSDD in premenopausal women in 2019, completing the clinical development path that MT-II could not.
Appetite suppression: Decreased appetite was reported as a consistent finding in the Dorr 1996 Phase 1 study and across subsequent ED trials. This MC3R/MC4R-mediated effect is pharmacologically predictable. No controlled human weight loss or appetite trial of MT-II was conducted. The appetite suppression has been conflated in grey-market promotion with fat loss claims; controlled human data on body composition effects do not exist.
Female sexual arousal data for MT-II is exploratory only; bremelanotide (profiled at order 21) is the completed development path and FDA-approved alternative. Appetite suppression is a documented pharmacological side effect, not a studied therapeutic application in humans. Body composition claims made in grey-market contexts have no controlled human evidence base.
The clinical outcome most relevant to the population actually using MT-II is not derived from controlled trials -- it is the harm profile of unregulated market use. Three documented sources of harm compound the intrinsic pharmacological risks:
Dosing inaccuracy: Laboratory analysis confirmed MT-II vials contain 43% to 88% of stated dose. This means users cannot titrate dose accurately even if they use the clinical trial doses as guidance. Under-dosing wastes money and fails to achieve intended effects. Over-dosing produces more severe adverse effects.
Contamination: Products from grey-market vendors are manufactured under no quality standard. Bacterial contamination, peptide degradation products, and unknown impurities are all plausible. The Van Hout and Bren (2015) review specifically documented contaminated product issues. No certificate of analysis from an independent laboratory can be assumed to be accurate for grey-market products.
Needle sharing: Community use patterns include needle sharing for injection, particularly in gym and tanning salon contexts. This directly transmits bloodborne pathogens (HIV, hepatitis C, hepatitis B).
The priapism cases (Mallory 2021, Dreyer 2019) document emergency presentations for spontaneous prolonged erections from MT-II use requiring medical intervention. Priapism causes ischemic damage to erectile tissue if untreated, potentially causing permanent erectile dysfunction -- the opposite of the intended effect.
The unregulated market harm profile substantially exceeds what Phase 1 and Phase 2 data would suggest from the intrinsic pharmacology. Dosing inaccuracy, contamination, and needle sharing all add real harm to the documented pharmacological adverse effects. For practitioners who encounter patients using MT-II, disclosure of use in the clinical context is essential for managing skin lesion changes and any acute presentations.
Loading: 250-500mcg daily until desired response. Maintenance: as needed.
MT-II has validated human PK and dosing data from Phase 1 and Phase 2 trials establishing 0.025 mg/kg as the preferred dose producing tanning and erectogenic effects with manageable (though substantial) nausea. The grey-market community uses flat doses (0.25 to 1.0 mg) rather than weight-based dosing, which the clinical trials used. This creates dosing inconsistency particularly at lower body weights. The compound is illegal to sell in the USA, UK, and Australia. Any product purchased through unregulated channels cannot be verified for purity, actual MT-II content (documented to range 43% to 88% of label claim), or sterility. Dermatological baseline mole mapping is recommended before any MT-II course, with follow-up during and after, given the naevi and melanoma signals. Any changes in existing moles require prompt dermatological evaluation. Priapism (sustained painful erection exceeding 4 hours) is a medical emergency requiring immediate hospital evaluation to prevent permanent erectile tissue damage.
MT-II sits at the junction of two approved compounds in this database. Afamelanotide (Melanotan I, Scenesse, profile #20) shares MT-II's tanning mechanism via MC1R but achieves it with high receptor selectivity and without the MC3R/MC4R-driven sexual and nausea effects; it is FDA-approved for EPP. Bremelanotide (PT-141, Vyleesi, profile #21) was derived directly from MT-II to isolate its sexually active metabolite; it received FDA approval in 2019 for HSDD. MT-II is the unrefined pharmacological parent that spawned two approved drugs while itself remaining unapproved. In the broader sexual function category, bremelanotide and kisspeptin (profile #19) represent the more developed clinical pathways. For tanning, afamelanotide is the only approved option.
The safety profile of MT-II is characterized by predictable acute adverse effects from non-selective melanocortin receptor activation and a concerning but uncertain long-term melanoma risk. The combination of these factors is why clinical development was abandoned despite demonstrated pharmacological efficacy.
Acute adverse effects from controlled clinical trials: Nausea was reported at all dose levels in the Dorr et al. (1996) Phase 1 study and in both Wessells ED trials. At the preferred dose of 0.025 mg/kg, 12.9% of subjects in Wessells 2000 had severe nausea. The stretching-yawning complex is a consistent, pharmacologically predictable finding from MC4R activation. Facial flushing, drowsiness, decreased appetite, and spontaneous erections occur predictably. These acute effects are dose-dependent and transient. At 0.03 mg/kg, the Dorr study documented WHO Grade II somnolence and fatigue in one of three subjects, marking the upper tolerated dose range.
The melanoma and naevi concern: Published peer-reviewed case reports document: eruptive melanocytic naevi (sudden development of multiple new moles) in multiple individuals after MT-II courses; at least one case of dysplastic naevi requiring excision in a 25-year-old man who developed more than 100 melanocytic nevi after 4 weeks of MT-II; and at least one case of melanoma in a 20-year-old woman after a 3 to 4-week MT-II course combined with sunbed use (Hjuler and Lorentzen, 2014, Dermatology). Additionally, darkening and morphological change in existing moles has been documented in multiple case reports. Melanonychia (nail darkening) has been reported. None of these cases establish causation. Multiple regulatory bodies cite them as sufficient cause for warning against use.
Rare but serious case-reported adverse events: Priapism (prolonged, painful erection requiring medical intervention) has been reported in multiple case publications including Mallory et al. (2021, Sexual Medicine) and Dreyer et al. (2019, BMJ Case Reports). Renal infarction has been reported. Rhabdomyolysis (muscle breakdown) has been reported, potentially fatal. These are case reports from unregulated market use and cannot be cleanly attributed to pure MT-II vs. product contamination.
Unregulated market safety: The compounding of safety concerns from the drug itself with the quality failures of the grey market is critical context. Verified laboratory analysis of MT-II vials marketed as containing 10 mg found actual content ranging from 4.32 to 8.84 mg -- meaning users cannot know their actual dose. Contamination, unknown impurities, and needle-sharing for injection (transmitting bloodborne pathogens) add substantially to the harm profile that controlled clinical trial data alone does not capture.
Melanotan II's story is a genuine cautionary tale in peptide pharmacology, not a reflexive regulatory overreach. The compound works: its erectogenic and tanning effects are real, documented in placebo-controlled human trials, and mechanistically well-understood. It failed to become a medicine not because the science was wrong but because the specific combination of a severe nausea burden and a documented melanoma safety signal made the risk-benefit calculation unacceptable for a cosmetic or elective indication.
The productive scientific legacy of MT-II is its contribution to melanocortin receptor pharmacology. By establishing MC4R as a validated erectile drug target in humans, the Wessells trials enabled bremelanotide (PT-141, Vyleesi), which addressed the nausea problem through structural optimization and received FDA approval in 2019. The compound that worked for a specific sexual dysfunction indication is in the database at order 21. MT-II itself is not.
The melanoma concern is real but not proven in controlled trials. The uncertainty is genuine: case reports are not controlled experiments, and UV co-exposure confounds attribution in most documented cases. What is not uncertain: multiple independent regulatory agencies with access to the full evidence base, including clinical development data not in the public domain, concluded the safety concern was sufficient to halt development and issue public warnings. The TGA does not halt drug development programs lightly.
For the grey-market community using MT-II for tanning and sexual function: the pharmacology is real, the safety signals are real, the product quality is not verifiable, and the regulatory prohibition on sale means quality oversight is absent. Dermatological monitoring (baseline mole mapping before use, follow-up during and after any course) is a minimum harm-reduction measure that dermatologists and regulatory agencies consistently recommend. Bremelanotide (via prescription) provides the sexually active indication through a FDA-approved, quality-controlled pathway.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use